The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.



  • Microbiome and immune system in cancer – Laurence Zitvogel (Gustave Roussy, Paris, France)
  • Microbiota-mediated metabolic health – Soraya Taleb (Paris-Centre de Recherche Cardiovasculaire, Paris,France)
  • Shaping of adaptive immunity by the microbiota – Hyun-Dong Chang (Deutsches Rheuma-Forschungszentrum Berlin, Germany)
  • Effects of non-antibiotics on the microbiome – Georg Zeller (EMBL Heidelberg, Germany)


  • Potential of fecal microbiota for early-stage detection of colorectal cancer – Georg Zeller (EMBL Heidelberg, Germany)
  • Crosstalk of the microbiome and epithelial cells – Dirk Haller (Technische Universität München, Germany)
  • Regulation of life span by the gut microbiome – Dario Valenzano (Max Planck Institute for Biology of Ageing, Germany)
  • Applying systems-biology to study the mechanistic interactions of the gut microbiota – Naama Geva-Zatorsky (Technion, Israel)
  • Gut microbiota-derived propionate reduces cancer cell proliferation in the liver – Laure Bindels (Université Catholique de Louvain, Belgium)
  • Microbiome restoration therapy in acute myeloid leukemia – Ronald Carter (Maat-Pharma, France)


  • Microbiome and immunotherapy in cancer – Giorgio Trinchieri (Center for Cancer Research/NCI/NIH, USA)
  • Interplay of innate lymphoid cells and the microbiota – Andreas Diefenbach (Charité – Universitätsmedizin Berlin, Germany)
  • The role of microbiota in GvHD and complications of allogeneic SCT – Ernst Holler (Universitätsklinikum Regensburg, Germany)
  • The intra-tumoral bacterial flora – potential implications – Mark Tangney (University College Cork, Ireland)


Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752
Tel: +32 2 880 62 70